Greechan Peter L, Koh Ryan G L, Yoo Paul B
Institute of Biomedical Engineering, University of Toronto, Toronto, ON, M5S 3E2, Canada.
KITE Research Institute, Toronto Rehabilitation Institute - University Health Network, Toronto, ON, Canada.
Bioelectron Med. 2025 Aug 15;11(1):19. doi: 10.1186/s42234-025-00181-w.
While there has been rapid progress in research aimed at developing device-based neuromodulation therapies for blood pressure (BP) disorders, there is a paucity of FDA-approved therapies. Currently, the only approved devices for treating resistant hypertension use renal denervation, however, this could soon change as clinical research progresses. With the evolution of interventional strategies for BP regulation, it is important to comprehend the developments to date in order to gauge directions for future research. The objective of this scoping review was to provide the current range of device-based BP neuromodulation approaches, overview salient characteristics of the included studies, address limitations, and detail avenues of further investigation.
Our review was conducted using the Preferred Reporting Items for Reviews and and Meta-analysis framework. The literature search was performed across the Web of Science Core Collection, Scopus, and Pubmed databases. The search yielded 3503 studies, of which 100 studies remained following the screening process. In the last 10 years, there has been an increase in the number of experimental neurostimulation studies detailing increases and decreases in BP. Of all the included studies, most adopted a non-randomized experimental approach (89%), used animal participants (65%), used invasive neuromodulation methods (74%), and performed acute experiments (84%). More studies documented only depressor responses (49%) compared to pressor responses (35%), and 13% reported both pressor and depressor responses using multiple neural targets.
This review addressed developments in device-based BP neuromodulation, highlighting a dominant focus on treating resistant hypertension compared to hypotensive disorders. While advancements in implantable electrodes have improved spatial selectivity of stimulation, non-invasive neurostimulation devices have become increasingly popular in recent years.
尽管在开发基于设备的血压(BP)疾病神经调节疗法的研究方面取得了快速进展,但美国食品药品监督管理局(FDA)批准的疗法却很少。目前,唯一被批准用于治疗顽固性高血压的设备采用肾去神经支配,然而,随着临床研究的进展,这种情况可能很快会改变。随着血压调节介入策略的发展,了解迄今为止的进展对于确定未来研究方向至关重要。本范围综述的目的是提供当前基于设备的血压神经调节方法的范围,概述纳入研究的显著特征,解决局限性,并详细说明进一步研究的途径。
我们的综述采用系统评价和Meta分析的首选报告项目(PRISMA)框架进行。在科学网核心合集、Scopus和PubMed数据库中进行文献检索。检索共得到3503项研究,经过筛选过程后,剩下100项研究。在过去10年中,详细描述血压升高和降低的实验性神经刺激研究数量有所增加。在所有纳入的研究中,大多数采用非随机实验方法(89%),使用动物参与者(65%),使用侵入性神经调节方法(74%),并进行急性实验(84%)。与升压反应(35%)相比,更多研究仅记录了降压反应(49%),13%的研究报告了使用多个神经靶点的升压和降压反应。
本综述阐述了基于设备的血压神经调节的进展,强调与低血压疾病相比,主要侧重于治疗顽固性高血压。虽然可植入电极的进步提高了刺激的空间选择性,但近年来非侵入性神经刺激设备越来越受欢迎。